<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297958</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A01041-46</org_study_id>
    <nct_id>NCT02297958</nct_id>
  </id_info>
  <brief_title>Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma</brief_title>
  <acronym>IFFaLCCO</acronym>
  <official_title>Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <brief_summary>
    <textblock>
      Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many&#xD;
      patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for&#xD;
      induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell&#xD;
      motility.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2015</start_date>
  <completion_date type="Actual">July 27, 2019</completion_date>
  <primary_completion_date type="Actual">July 27, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between cleaved FasL level ans neoadjuvant chemotherapy tumor response</measure>
    <time_frame>surgery</time_frame>
    <description>Main outcome is cleaved FasL level and correlation with neoadjuvant chemotherapy tumor response, evaluated during surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of tumoral T cells</measure>
    <time_frame>surgery</time_frame>
    <description>Identification of tumoral T cells with FACS analysis of dissociated tumor. Different T cells will be studies: Treg/Th17/Th1/Th2 using antibodies against: CD45/CD3/CD4/CD25/FOXP3 (Treg), CD45/CD3/CD4/IL17A (Th17), CD45/CD3/CD4/CD8/IL4/INF (TCD8 and LTCD4 Th1 et Th2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival rate</measure>
    <time_frame>18 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>18 months after surgery</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with ovarian carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Pre-Inclusion Criteria:&#xD;
&#xD;
        - Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125)&#xD;
        and radiological data (CT)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological ovarian carcinoma diagnosed at pathological analysis after surgery.&#xD;
&#xD;
          -  Neo adjuvant chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no neo-adjuvant chemotherapy&#xD;
&#xD;
          -  no ovarian carcinoma at final pathological analysis&#xD;
&#xD;
          -  less than 18 years old.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Lavoue, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Gyn√©cologie</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

